Pay in 4 interest-free payments of $6.28 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
SEVERABILITY: If any provision of this disclaimer is deemed invalid or unenforceable, the remaining provisions shall continue in full force and effect
Unlike growth hormone, which would worsen glycemic control, AOD-9604 can be used in these populations without concerns about blood sugar elevation or insulin resistance progression
MOTS-c is improving insulin sensitivity and metabolic flexibility
The molecule was developed by the Australian pharmaceutical company Metabolic Pharmaceuticals (in collaboration with Monash University) and advanced through Phase I safety trials and a Phase IIb obesity efficacy trial enrolling approximately 900 participants in total
The injection should be given in the morning, preferably 30-60 minutes before the first meal
